Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor typically used for psoriatic arthritis and plaque psoriasis, appears to be a promising therapeutic option for ReA. This evidence concerns the gene PDE4A and psoriasis vulgaris.